Trials that could prevent the disease from returning are to be expanded over the next year in world-first programme
Trials that could prevent the disease from returning are to be expanded over the next year in world-first programme
Copy link
The jab uses mRNA technology to train the immune system to fight cancerous cells
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
A promising triple-action cancer jab being trialled at the Royal Marsden has shown encouraging results for some patients with…
Non-mRNA jab targeting common mutations in pancreatic and bowel cancers could lower risk of relapse
Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine
The effectiveness of amivantamab is being evaluated in around 60 clinical trials worldwide.
